GRIP
GRIP Molecular Technologies is pioneering the next generation of CRISPR-based diagnostics with a molecular test platform for lateral flow assays. Powered by a CRISPR protease engine, GRIP's diagnostic platform detects pathogen RNA and amplifies signal in minutes, providing accurate results without nucleic acid amplification. The technology operates at room temperature, is pathogen and sample agnostic, and uses…
Funding snapshot
About
GRIP Molecular Technologies is pioneering the next generation of CRISPR-based diagnostics with a molecular test platform for lateral flow assays. Powered by a CRISPR protease engine, GRIP's diagnostic platform detects pathogen RNA and amplifies signal in minutes, providing accurate results without nucleic acid amplification. The technology operates at room temperature, is pathogen and sample agnostic, and uses stable proteins as reporter substrates to avoid false positives from nucleases. The platform supports multiple readout methods including lateral flow assays, electrochemical tests, and colorimetric assays, with plug-and-play manufacturing that integrates into proven immunoassay pipelines. GRIP targets the over $2 billion per year global market for point-of-care diagnostics for STIs, UTIs, and upper respiratory infections. Founded in 2019, headquartered in Saint Paul, United States, The company has raised $14.7M at the Series A stage, backed by investors including EvoNexus, gBETA Medtech, JLABS..
Business model
Infectious Diseases > In Vitro Diagnostic Tests > Diversified > Point Of Care,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Microbial Testing > Infectious Diseases
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.